Platinum Nephrotoxicity: Tubules and Electrolytes

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

A toxicity decision should consider curative potential, alternatives, and reversibility. Avoid treating all platinum agents as clinically interchangeable.

Platinum agents can affect tubules and electrolytes. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Platinum agents can affect tubules and electrolytes. Glomerulus — Verify the renal estimate before a cycle; Proximal tubule — Tubular toxicity depends on agent and exposure; Loop / distal tubule — Magnesium and other losses may develop; Collecting system — Follow delayed changes after treatment. Platinum agents are not interchangeable. Separate toxicity from other causes of AKI. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Separate the platinum agents

Cisplatin commonly raises concerns about tubular injury and magnesium wasting; carboplatin dosing is linked to target exposure and a kidney-function estimate. Do not use a cisplatin toxicity rule as a carboplatin dosing formula, or assume the agents are interchangeable alternatives for cancer efficacy.

Identify susceptibility

Baseline CKD, dehydration, interacting drugs, cumulative exposure, and treatment intensity can modify risk.

Check more than creatinine

Magnesium, potassium, phosphate, volume status, and symptoms can reveal tubular dysfunction before or beyond a major filtration change.

Verify the renal estimate before the cycle

Review recent kidney trajectory and whether the dosing protocol requires measured or estimated GFR. A stable creatinine equation can mislead during AKI or marked muscle loss. Coordinate the prescribed target exposure, hydration, magnesium support, and dose decision with oncology and pharmacy.

Follow delayed effects

Electrolyte wasting may persist after exposure. Repeated replacement without investigating the ongoing renal loss can miss the mechanism.

Preserve cancer and kidney goals

A toxicity decision should consider curative potential, alternatives, and reversibility. Avoid treating all platinum agents as clinically interchangeable.

Continue learning